U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C5H9Cl2N3O2
Molecular Weight 214.05
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CARMUSTINE

SMILES

ClCCNC(=O)N(CCCl)N=O

InChI

InChIKey=DLGOEMSEDOSKAD-UHFFFAOYSA-N
InChI=1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11)

HIDE SMILES / InChI

Molecular Formula C5H9Cl2N3O2
Molecular Weight 214.05
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/cdi/carmustine.html http://www.rxlist.com/bicnu-drug.htm http://www.wikidoc.org/index.php/Carmustine_(injection)

Carmustine is a cancer medication that interferes with the growth and spread of cancer cells in the body. Carmustine is used to treat brain tumors, Hodgkin's disease, multiple myeloma, and non-Hodgkin's lymphoma. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross-resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins. Pulmonary toxicity characterized by pulmonary infiltrates and/or fibrosis has been reported to occur from 9 days to 43 months after treatment with BiCNU and related nitrosoureas. A frequent and serious toxicity of BiCNU is delayed myelosuppression. Nausea and vomiting after intravenous administration of BiCNU are noted frequently. Greater myelotoxicity (e.g., leukopenia and neutropenia) has been reported when carmustine was combined with cimetidine.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
BICNU

Approved Use

GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1)

Launch Date

1977
Primary
BICNU

Approved Use

GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1)

Launch Date

1977
Primary
BICNU

Approved Use

GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1)

Launch Date

1977
Primary
BICNU

Approved Use

GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1)

Launch Date

1977
Primary
BICNU

Approved Use

GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1)

Launch Date

1977
Secondary
BICNU

Approved Use

GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1)

Launch Date

1977
Secondary
BICNU

Approved Use

GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1)

Launch Date

1977
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.7 μg/mL
600 mg/m² 1 times / day steady-state, intravenous
dose: 600 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered: Cyclophosphamide | Cisplatin
CARMUSTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7.8 μM
1000 mg/m² single, intravenous
dose: 1000 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CARMUSTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
456 μg × min/mL
600 mg/m² 1 times / day steady-state, intravenous
dose: 600 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered: Cyclophosphamide | Cisplatin
CARMUSTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
538 μM × min
1000 mg/m² single, intravenous
dose: 1000 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CARMUSTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
18 min
600 mg/m² 1 times / day steady-state, intravenous
dose: 600 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered: Cyclophosphamide | Cisplatin
CARMUSTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
23%
1000 mg/m² single, intravenous
dose: 1000 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CARMUSTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
150 mg/m2 1 times / 7 weeks multiple, intravenous
MTD
Dose: 150 mg/m2, 1 times / 7 weeks
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / 7 weeks
Co-administed with::
IFN-a, s.c(12 x 10(6) units/m2; Days 1-3 each week of a 7-week cycle.)
Sources: Page: p.299, 300
unhealthy, 26-66
n = 11
Health Status: unhealthy
Condition: Glioma
Age Group: 26-66
Sex: M+F
Population Size: 11
Sources: Page: p.299, 300
DLT: Leukopenia, Thrombocytopenia...
Disc. AE: Pulmonary toxicity...
Dose limiting toxicities:
Leukopenia (grade 3-4, 45%)
Thrombocytopenia (grade 3-4, 27%)
AEs leading to
discontinuation/dose reduction:
Pulmonary toxicity (9%)
Sources: Page: p.299, 300
125 mg/m2 1 times / 6 weeks multiple, intravenous
MTD
Dose: 125 mg/m2, 1 times / 6 weeks
Route: intravenous
Route: multiple
Dose: 125 mg/m2, 1 times / 6 weeks
Co-administed with::
streptozocin, i.v(2 g/m2, single)
Sources: Page: p.258
unhealthy, 31-79
n = 24
Health Status: unhealthy
Condition: Advanced cancer
Age Group: 31-79
Sex: M+F
Population Size: 24
Sources: Page: p.258
DLT: Thrombocytopenia...
Disc. AE: Adult respiratory distress syndrome...
Dose limiting toxicities:
Thrombocytopenia (grade 3-4)
AEs leading to
discontinuation/dose reduction:
Adult respiratory distress syndrome (grade 5, 4.2%)
Sources: Page: p.258
200 mg/m2 1 times / 6 weeks multiple, intravenous (max)
Recommended
Dose: 200 mg/m2, 1 times / 6 weeks
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / 6 weeks
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Brain tumors| Multiple myeloma| Hodgkin's lymphoma| Non-Hodgkin's lymphomas
Sources: Page: p.1
Disc. AE: Marrow depression of, Thrombocytopenia...
AEs leading to
discontinuation/dose reduction:
Marrow depression of
Thrombocytopenia
Leukopenia
Pulmonary toxicity
Administration site extravasation
Carcinogenicity
Fetal damage
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Pulmonary toxicity 9%
Disc. AE
150 mg/m2 1 times / 7 weeks multiple, intravenous
MTD
Dose: 150 mg/m2, 1 times / 7 weeks
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / 7 weeks
Co-administed with::
IFN-a, s.c(12 x 10(6) units/m2; Days 1-3 each week of a 7-week cycle.)
Sources: Page: p.299, 300
unhealthy, 26-66
n = 11
Health Status: unhealthy
Condition: Glioma
Age Group: 26-66
Sex: M+F
Population Size: 11
Sources: Page: p.299, 300
Thrombocytopenia grade 3-4, 27%
DLT
150 mg/m2 1 times / 7 weeks multiple, intravenous
MTD
Dose: 150 mg/m2, 1 times / 7 weeks
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / 7 weeks
Co-administed with::
IFN-a, s.c(12 x 10(6) units/m2; Days 1-3 each week of a 7-week cycle.)
Sources: Page: p.299, 300
unhealthy, 26-66
n = 11
Health Status: unhealthy
Condition: Glioma
Age Group: 26-66
Sex: M+F
Population Size: 11
Sources: Page: p.299, 300
Leukopenia grade 3-4, 45%
DLT
150 mg/m2 1 times / 7 weeks multiple, intravenous
MTD
Dose: 150 mg/m2, 1 times / 7 weeks
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / 7 weeks
Co-administed with::
IFN-a, s.c(12 x 10(6) units/m2; Days 1-3 each week of a 7-week cycle.)
Sources: Page: p.299, 300
unhealthy, 26-66
n = 11
Health Status: unhealthy
Condition: Glioma
Age Group: 26-66
Sex: M+F
Population Size: 11
Sources: Page: p.299, 300
Thrombocytopenia grade 3-4
DLT
125 mg/m2 1 times / 6 weeks multiple, intravenous
MTD
Dose: 125 mg/m2, 1 times / 6 weeks
Route: intravenous
Route: multiple
Dose: 125 mg/m2, 1 times / 6 weeks
Co-administed with::
streptozocin, i.v(2 g/m2, single)
Sources: Page: p.258
unhealthy, 31-79
n = 24
Health Status: unhealthy
Condition: Advanced cancer
Age Group: 31-79
Sex: M+F
Population Size: 24
Sources: Page: p.258
Adult respiratory distress syndrome grade 5, 4.2%
Disc. AE
125 mg/m2 1 times / 6 weeks multiple, intravenous
MTD
Dose: 125 mg/m2, 1 times / 6 weeks
Route: intravenous
Route: multiple
Dose: 125 mg/m2, 1 times / 6 weeks
Co-administed with::
streptozocin, i.v(2 g/m2, single)
Sources: Page: p.258
unhealthy, 31-79
n = 24
Health Status: unhealthy
Condition: Advanced cancer
Age Group: 31-79
Sex: M+F
Population Size: 24
Sources: Page: p.258
Administration site extravasation Disc. AE
200 mg/m2 1 times / 6 weeks multiple, intravenous (max)
Recommended
Dose: 200 mg/m2, 1 times / 6 weeks
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / 6 weeks
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Brain tumors| Multiple myeloma| Hodgkin's lymphoma| Non-Hodgkin's lymphomas
Sources: Page: p.1
Carcinogenicity Disc. AE
200 mg/m2 1 times / 6 weeks multiple, intravenous (max)
Recommended
Dose: 200 mg/m2, 1 times / 6 weeks
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / 6 weeks
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Brain tumors| Multiple myeloma| Hodgkin's lymphoma| Non-Hodgkin's lymphomas
Sources: Page: p.1
Fetal damage Disc. AE
200 mg/m2 1 times / 6 weeks multiple, intravenous (max)
Recommended
Dose: 200 mg/m2, 1 times / 6 weeks
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / 6 weeks
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Brain tumors| Multiple myeloma| Hodgkin's lymphoma| Non-Hodgkin's lymphomas
Sources: Page: p.1
Leukopenia Disc. AE
200 mg/m2 1 times / 6 weeks multiple, intravenous (max)
Recommended
Dose: 200 mg/m2, 1 times / 6 weeks
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / 6 weeks
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Brain tumors| Multiple myeloma| Hodgkin's lymphoma| Non-Hodgkin's lymphomas
Sources: Page: p.1
Marrow depression of Disc. AE
200 mg/m2 1 times / 6 weeks multiple, intravenous (max)
Recommended
Dose: 200 mg/m2, 1 times / 6 weeks
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / 6 weeks
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Brain tumors| Multiple myeloma| Hodgkin's lymphoma| Non-Hodgkin's lymphomas
Sources: Page: p.1
Pulmonary toxicity Disc. AE
200 mg/m2 1 times / 6 weeks multiple, intravenous (max)
Recommended
Dose: 200 mg/m2, 1 times / 6 weeks
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / 6 weeks
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Brain tumors| Multiple myeloma| Hodgkin's lymphoma| Non-Hodgkin's lymphomas
Sources: Page: p.1
Thrombocytopenia Disc. AE
200 mg/m2 1 times / 6 weeks multiple, intravenous (max)
Recommended
Dose: 200 mg/m2, 1 times / 6 weeks
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / 6 weeks
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Brain tumors| Multiple myeloma| Hodgkin's lymphoma| Non-Hodgkin's lymphomas
Sources: Page: p.1
PubMed

PubMed

TitleDatePubMed
Cytoprotective effects of trimetazidine in carmustine cholestasis.
1999 Jul
Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule.
1999 Jun
Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy.
2000 Sep
Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients.
2001 Apr
The role of glutathione reductase in the cytotoxicity of chromium (VI) in isolated rat hepatocytes.
2001 Apr 16
Temozolomide in combination with other cytotoxic agents.
2001 Aug
Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
2001 Feb
Current treatment of Cutaneous T-Cell Lymphoma.
2001 Feb
Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia.
2001 Feb 15
Detecting treatment-by-centre interaction in multi-centre clinical trials.
2001 Jan 30
Amifostine does not protect malignant lymphoma cell lines from the cytotoxic effects of various chemotherapeutics in vitro.
2001 Jul
Acyl derivatives of demethylpenclomedine, an antitumor-active, non-neurotoxic metabolites of penclomedine.
2001 Jul
Anticancer therapy by overexpression of superoxide dismutase.
2001 Jun
Heterogeneous methylation of the O(6)-methylguanine-DNA methyltransferase promoter in immortalized IMR90 cell lines.
2001 Jun
Pharmacodynamics of high-dose chemotherapy.
2001 Mar
Inactivation of human O(6)-alkylguanine-DNA alkyltransferase by modified oligodeoxyribonucleotides containing O(6)-benzylguanine.
2001 Mar
Protection of mammalian cells against chemotherapeutic agents thiotepa, 1,3-N,N'-bis(2-chloroethyl)-N-nitrosourea, and mafosfamide using the DNA base excision repair genes Fpg and alpha-hOgg1: implications for protective gene therapy applications.
2001 Mar
Both extraneuronal monoamine transporter and O(6)-methylguanine-DNA methyltransferase expression influence the antitumor efficacy of 2-chloroethyl-3-sarcosinamide- 1-nitrosourea in human tumor xenografts.
2001 Mar
The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
2001 Mar 1
The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
2001 Mar 1
Long-term results of a phase-II-pilot trial on preoperative high-dose chemotherapy with stem cell rescue in patients with cancer of the upper gastrointestinal tract.
2001 Mar-Apr
Cellular titration of apoptosis with steady state concentrations of H(2)O(2): submicromolar levels of H(2)O(2) induce apoptosis through Fenton chemistry independent of the cellular thiol state.
2001 May 1
Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.
2001 Oct
Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs.
2001 Sep
Accelerated hazards regression model and its adequacy for censored survival data.
2001 Sep
Nitric oxide and free stable nitroxyl radicals in the mechanism of biological action of the spin-labeled compounds.
2001 Sep
Use of pure t-butanol as a solvent for freeze-drying: a case study.
2001 Sep 11
Escherichia coli FPG and human OGG1 reduce DNA damage and cytotoxicity by BCNU in human lung cells.
2002 Jan
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: The recommended dose of carmustine is eight 7.7 mg wafers for a total of 61.6 mg implanted intracranially.
The recommended dose of BiCNU as a single agent in previously untreated patients is 150 to 200 mg/m2 intravenously every 6 weeks. This may be given as a single dose or divided into daily injections such as 75 to 100 mg/m2 on 2 successive days.
Route of Administration: Other
In Vitro Use Guide
Sources: Doi:10.4236/nm.2011.24050
LD50 values for the short term glioma tumour cultures lay in the range 10 - 90 μg/ml for Carmustine.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:02:18 GMT 2023
Edited
by admin
on Fri Dec 15 15:02:18 GMT 2023
Record UNII
U68WG3173Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CARMUSTINE
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
CARMUSTINE [EP IMPURITY]
Common Name English
GLIADEL
Brand Name English
SRI-1720
Code English
BISCHLOROETHYL NITROSOUREA [IARC]
Common Name English
CARMUSTINE [JAN]
Common Name English
Carmustine [WHO-DD]
Common Name English
DTI-015
Code English
CARMUSTINE [EP MONOGRAPH]
Common Name English
SK-27702
Code English
CARMUSTINE [MI]
Common Name English
carmustine [INN]
Common Name English
CARMUSTINE [USAN]
Common Name English
CARMUSTINE [MART.]
Common Name English
UREA, N,N'-BIS(2-CHLOROETHYL)-N-NITROSO-
Systematic Name English
CARMUSTINE [USP MONOGRAPH]
Common Name English
CAMUSTINE [VANDF]
Common Name English
CARMUSTINE [HSDB]
Common Name English
BICNU
Brand Name English
CARMUBRIS
Brand Name English
NSC-409962
Code English
FDA-0345
Code English
BCNU
Code English
CARMUSTINE [USP-RS]
Common Name English
BECENUN
Brand Name English
CARMUSTINE [ORANGE BOOK]
Common Name English
1,3-Bis(2-chloroethyl)-1-nitrosourea
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C699
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
LIVERTOX NBK548307
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
FDA ORPHAN DRUG 37089
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
WHO-ATC L01AD01
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
NDF-RT N0000000236
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
NDF-RT N0000175558
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
WHO-VATC QL01AD01
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
FDA ORPHAN DRUG 606517
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
FDA ORPHAN DRUG 134500
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
EU-Orphan Drug EU/3/02/085
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
FDA ORPHAN DRUG 801420
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
Code System Code Type Description
DAILYMED
U68WG3173Y
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
PRIMARY
EPA CompTox
DTXSID8022743
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
PRIMARY
INN
2959
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
PRIMARY
FDA UNII
U68WG3173Y
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
PRIMARY
WIKIPEDIA
CARMUSTINE
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
PRIMARY
ECHA (EC/EINECS)
205-838-2
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
PRIMARY
MESH
D002330
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
PRIMARY
DRUG CENTRAL
512
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
PRIMARY
NCI_THESAURUS
C349
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
PRIMARY
PUBCHEM
2578
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
PRIMARY
SMS_ID
100000090209
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
PRIMARY
CHEBI
3423
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
PRIMARY
IUPHAR
6800
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
PRIMARY
MERCK INDEX
m3115
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
PRIMARY Merck Index
DRUG BANK
DB00262
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
PRIMARY
ChEMBL
CHEMBL513
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
PRIMARY
RXCUI
2105
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
PRIMARY RxNorm
CAS
154-93-8
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
PRIMARY
EVMPD
SUB06132MIG
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
PRIMARY
RS_ITEM_NUM
1096724
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
PRIMARY
LACTMED
Carmustine
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
PRIMARY
HSDB
7761
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
PRIMARY
NSC
409962
Created by admin on Fri Dec 15 15:02:18 GMT 2023 , Edited by admin on Fri Dec 15 15:02:18 GMT 2023
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (UV)
EP
BASIS OF STRENGTH->SUBSTANCE
solvent-free basis
ASSAY (HPLC)
USP
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC